Sapindoside B 

Sapindoside B is a substance with hepatoprotective activity, and also acts as a cytochrome P-450 (cytochrome P-450) inhibitor, antibacterial agent and membrane-disrupting agent. Sapindoside B reversibly inhibits the content of cytochrome P-450 in liver microsomes, suppresses the phenobarbital-induced increase in enzyme content, reduces the production of active metabolites mediated by cytochrome P-450, and alleviates hepatotoxic injury. Sapindoside B binds to Cutibacterium acnes lipase, reduces lipase activity, inhibits biofilm formation, and decreases bacterial adhesion. Sapindoside B exhibits cytotoxicity against human cancer, liver cancer, leukemia and glioblastoma cells. Sapindoside B inhibits mycelial growth of phytopathogenic fungal strains, possesses antibacterial activity against dermatophytes, and also has hemolytic/membrane-lytic activity. Sapindoside B can be used in research related to liver injury, Cutibacterium acnes biofilm-associated infections, gastric cancer, carcinoma, promyelocytic leukemia, glioblastoma, apple scab and grape gray mold^{[1][2][3][4][5]}.

Sapindoside B (0.1MIC-0.5MIC; 3 d) dose-dependently inhibits early biofilm formation and mature biofilms of Cutibacterium acnes ATCC 6919 at sub-MIC concentrations, suppresses the adhesion of Cutibacterium acnes ATCC 6919, reduces cell surface hydrophobicity, decreases extracellular polysaccharide production in biofilms, inhibits lipase activity in biofilms, and disrupts the structure of early-formed biofilms^[3].
Sapindoside B (0.5MIC; 3 d) reduces the biomass, thickness and diffusion distance of early-formed Cutibacterium acnes ATCC 6919 biofilms, while increases their roughness. It downregulates the expression of biofilm-related genes^[3].
Sapindoside B (0.5-50 μM; 72 h) exhibits moderate cytotoxicity against human gastric cancer cells SGC-7901, human hepatocellular carcinoma cells HepG2, human promyelocytic leukemia cells HL-60, and human glioblastoma cells U251MG, with IC₅₀ values ranging from 4.24 μM to 15.37 μM^[4].
Sapindoside B (5 mg per 100 mL; treated for 21 days against *V. inaequalis* and 4 days against *B. cinerea*) inhibits mycelial growth of *Venturia inaequalis* V1 by 46% and mycelial growth of *Botrytis cinerea* B05.10 by 43% under in vitro conditions^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sapindoside B (20 mg/kg; s.c.; 2 or 3 times at 8-hour intervals) suppresses hepatic microsomal cytochrome P-450 content by 55-60% in healthy Kunming strain male mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

883.07

C₄₆H₇₄O₁₆

30994-75-3

Solid

White to off-white

C[C@@]12C([C@@]3([H])[C@@](CC2)(CCC(C)(C3)C)C(O)=O)=CC[C@@]4([H])[C@]1(CC[C@]5([H])[C@@]4(CC[C@@H]([C@@]5(C)CO)O[C@H]6[C@@H]([C@H]([C@H](CO6)O)O)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)O)C)C

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

• [1]. Shi JZ, et al. Effect of alpha-hederin and sapindoside B on hepatic microsomal cytochrome P-450 in mice. Zhongguo yao li xue bao = Acta Pharmacologica Sinica. 1996 May;17(3):264-266.

  [2]. Sawada H, et al. Saponins from leaves of Acanthopanax sieboldianus. Phytochemistry. 1993;34(4):1117-1121.  [Content Brief]

  [3]. Wei MP, et al. Synergistic combination of Sapindoside A and B: A novel antibiofilm agent against Cutibacterium acnes. Microbiol Res. 2022;254:126912.

  [4]. Zhao M, et al. Cytotoxic triterpenoid saponins from Clematis tangutica. Phytochemistry. 2016;130:228-237.

  [5]. Porsche FM, et al. Antifungal Activity of Saponins from the Fruit Pericarp of Sapindus mukorossi against Venturia inaequalis and Botrytis cinerea. Plant Dis. 2018;102(5):991-1000.